
## References

9. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367:262. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)68037-9/abstract

10. Behr ER, Veysey MJ, Berry D, et al. Optimum dose of digoxin. Lancet 1997; 349(9068):1845 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)61735-7/fulltext

11. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525–33. http://www.nejm.org/doi/full/10.1056/NEJM199702203360801

12. NICE. General principles for treating people with stable angina. In Stable angina: Management [CG126], Chapter 1.3. 2011, updated 2016. https://www.nice.org.uk/guidance/cg126/chapter/1-Guidance#general-principles-for-treating-people-with-stable-angina

13. NICE. Chest pain of recent onset: Assessment and diagnosis [CG95]. 2010, updated 2016. http://www.nice.org.uk/guidance/CG95

14. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37(3):267–315. http://eurheartj.oxfordjournals.org/content/37/3/267.long

15. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20):2569–619. http://eurheartj.oxfordjournals.org/content/33/20/2569.long

16. Junghans C. Risk assessment after acute coronary syndrome. BMJ 2006; 333:1080. http://www.bmj.com/content/333/7578/1079

17. Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation 2008; 118:1768–75. http://circ.ahajournals.org/content/118/17/1768.long

18. DVLA. Cardiovascular disorders: Assessing fitness to drive. March 2016. https://www.gov.uk/guidance/cardiovascular-disorders-assessing-fitness-to-drive

19. Gorenek B, Lundqvist C, Terradellas J, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Eur Heart J Acute Cardiovasc Care 2015; 4(4):386

20. Matteson EL, Kluge FJ. Think clearly, be sincere, act calmly: Adolf Kussmaul (February 22, 1822-May 28, 1902) and his relevance to medicine in the 21st century. Curr Opin Rheumatol 2003; 15(1):29–34

21. Massimo M. Minimally invasive coronary surgery: fad or future? BMJ 1998; 316:88

22. NICE. Off-pump coronary artery bypass grafting [IPG377]. 2011. http://guidance.nice.org.uk/IPG377

23. Brown WR, Moody DM, Venkata R, Challa VR, et al. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. Stroke 2000; 31:707–13. http://stroke.ahajournals.org/content/31/3/707

24. Perez-Silva A, Merino J. Frequent ventricular extrasystoles: significance, prognosis and treatment. ESC E-J Cardiol Pract 2011; 9(17). http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-9/Frequent-ventricular-extrasystoles-significance-prognosis-and-treatment

25. NICE. Atrial fibrillation: Management. 2014. https://www.nice.org.uk/guidance/cg180/chapter/1-Recommendations

26. Lubitz SA, Magnani JW, Ellinor PT, et al. Atrial fibrillation and death after myocardial infarction: risk marker or causal mediator? Circulation 2011; 123:2063–5. http://circ.ahajournals.org/content/123/19/2094.abstract

27. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825–33. http://www.nejm.org/doi/full/10.1056/NEJMoa021328

28. Oral H. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354(9):934–41. http://www.nejm.org/doi/full/10.1056/NEJMoa050955

29. Phang R, Prutkin J, Ganz L. Overview of atrial flutter. UpToDate®. 2015. http://www.uptodate.com/contents/overview-of-atrial-flutter?source=search_result&search=atrial+flutter&selectedTitle=1~150

30. Mant J. Warfarin vs aspirin for stroke prevention in elderly with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493–503. http://www.thelancet.com/journals/lancet/article/PIIS0140673607612331/abstract

31. Bristow M, Saxon L, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350(21):2140–50. http://www.nejm.org/doi/full/10.1056/NEJMoa032423

32. NICE. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure [TA314]. 2014. https://www.nice.org.uk/guidance/ta314

33. NICE. Chronic heart failure [CG108]. 2010. https://www.nice.org.uk/guidance/cg108

34. Patient. Palliative care of heart failure. 2016. http://www.patient.co.uk/showdoc/40024526/

35. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285(26):1441–6. http://www.nejm.org/doi/full/10.1056/NEJM197112232852601

36. Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. BMJ 1994; 308:321–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539274/

37. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48(5 Suppl):S101–9. http://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2000.tb03119.x/abstract

38. Cleland JG, McGowan J, Clark A, et al. The evidence for beta blockers in heart failure. BMJ 1999; 318:824–5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1115260/

39. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52(3):190–9

40. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709–17. http://content.nejm.org/cgi/reprint/341/10/709.pdf

41. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20):2049–57. http://content.nejm.org/cgi/content/full/351/20/2049